BDNF and psychotic disorder: This review synthesizes current evidence comparing peripheral BDNF levels in UHR populations with those in healthy controls (HCs), first-episode psychosis (FEP), and chronic schizophrenia (CS), focusing on BDNF’s potential relevance as a biomarker of psychosis risk and subsequent clinical course.